Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma

SIMPLE SUMMARY: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard treatments in patients with EGFR-mutated lung adenocarcinoma. However, the clinical data regarding EGFR-TKI efficacy in patients with poor performance status (PS ≥ 2) are limited. We reviewed the cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chiao-En, Chang, Ching-Fu, Huang, Chen-Yang, Yang, Cheng-Ta, Kuo, Chih-Hsi Scott, Hsu, Ping-Chih, Chang, John Wen-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833436/
https://www.ncbi.nlm.nih.gov/pubmed/35158940
http://dx.doi.org/10.3390/cancers14030674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833436/
https://www.ncbi.nlm.nih.gov/pubmed/35158940
http://dx.doi.org/10.3390/cancers14030674

Ejemplares similares